CC BY-NC-ND 4.0 · J Neurol Surg Rep 2022; 83(03): e80-e82
DOI: 10.1055/s-0042-1753519
Skull Base Oncology Case Series

Esthesioneuroblastoma (Olfactory Neuroblastoma): Overview and Extent of Surgical Approach and Skull Base Resection

Emily E. Karp
1   Department of Otolaryngology – Head & Neck Surgery, Mayo Clinic, Rochester, Minnesota, United States
,
1   Department of Otolaryngology – Head & Neck Surgery, Mayo Clinic, Rochester, Minnesota, United States
2   Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota, United States
,
Garret Choby
1   Department of Otolaryngology – Head & Neck Surgery, Mayo Clinic, Rochester, Minnesota, United States
2   Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota, United States
› Institutsangaben

Abstract

Esthesioneuroblastoma is a rare malignancy originating from the olfactory epithelium. Treatment consists of surgical resection with strong consideration for adjuvant treatment in advanced Kadish stage and high Hyams grade. In the modern era, overall outcomes for esthesioneuroblastoma are favorable compared with many other sinonasal malignancies with 5-year overall survival estimated to be 80%. When selecting the optimal surgical approach, the surgeon must consider the approach that will allow for a negative margin resection and adequate reconstruction. In appropriately selected patients, endoscopic outcomes appear at least equivalent to open approaches and unilateral endoscopic approach may be used in select olfactory preservation cases.



Publikationsverlauf

Eingereicht: 19. Mai 2022

Angenommen: 29. Mai 2022

Artikel online veröffentlicht:
10. Juli 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Wang EW, Zanation AM, Gardner PA. et al. ICAR: endoscopic skull-base surgery. Int Forum Allergy Rhinol 2019; 9 (S3): S145-S365
  • 2 Lechner M, Takahashi Y, Turri-Zanoni M. et al. Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. Eur J Cancer 2022; 162: 221-236
  • 3 McMillian RA, Van Gompel JJ, Link MJ. et al. Long-term oncologic outcomes in esthesioneuroblastoma: an institutional experience of 143 patients. Int Forum Allergy Rhinol Published online April 6, 2022 DOI: 10.1002/ALR.23007.
  • 4 Miller KC, Marinelli JP, Janus JR. et al. Induction therapy prior to surgical resection for patients presenting with locally advanced esthesioneuroblastoma. J Neurol Surg B Skull Base 2021; 82 (Suppl. 03) e131-e137
  • 5 Harvey RJ, Nalavenkata S, Sacks R. et al. Survival outcomes for stage-matched endoscopic and open resection of olfactory neuroblastoma. Head Neck 2017; 39 (12) 2425-2432
  • 6 Fu TS, Monteiro E, Muhanna N, Goldstein DP, de Almeida JR. Comparison of outcomes for open versus endoscopic approaches for olfactory neuroblastoma: a systematic review and individual participant data meta-analysis. Head Neck 2016; 38 (Suppl. 01) E2306-E2316
  • 7 Gompel JJV, Janus JR, Hughes JD. et al. Esthesioneuroblastoma and olfactory preservation: is it reasonable to attempt smell preservation?. J Neurol Surg B Skull Base 2018; 79 (02) 184-188
  • 8 Tajudeen BA, Adappa ND, Kuan EC. et al. Smell preservation following endoscopic unilateral resection of esthesioneuroblastoma: a multi-institutional experience. Int Forum Allergy Rhinol 2016; 6 (10) 1047-1050
  • 9 Wessell A, Singh A, Litvack Z. Preservation of olfaction after unilateral endoscopic approach for resection of esthesioneuroblastoma. J Neurol Surg Rep 2014; 75 (01) e149-e153
  • 10 Abiri A. et al. Postoperative protocols following endoscopic skull base surgery: An evidence based review with recommendation. Int Forum Aller Rhinol 2022; PMID 35678720